This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.62% per year. These returns cover a period from January 1, 1988 through June 2, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
earnings-consensus: Archive
Wall Street Analysts See an 80.44% Upside in ODP Corp. (ODP): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for ODP Corp. (ODP) points to an 80.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ODPNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Does Concentra (CON) Have the Potential to Rally 30.84% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Concentra (CON) points to a 30.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
CONNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe Avadel (AVDL) Could Rally 100.21%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Avadel (AVDL) points to a 100.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
AVDLNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe Great Lakes Dredge & Dock (GLDD) Could Rally 33.93%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Great Lakes Dredge & Dock (GLDD) points to a 33.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
GLDDNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Does CryoPort (CYRX) Have the Potential to Rally 54.74% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for CryoPort (CYRX) points to a 54.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
CYRXNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
How Much Upside is Left in Herbalife Ltd (HLF)? Wall Street Analysts Think 28.83%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 28.8% in Herbalife Ltd (HLF). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
HLFPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Can PureCycle Technologies (PCT) Climb 67.35% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 67.4% in PureCycle Technologies (PCT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
PCTPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Predict a 132.5% Upside in NewAmsterdam Pharma Company N.V. (NAMS): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 132.5% in NewAmsterdam Pharma Company N.V. (NAMS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
NAMSPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 62.89% Upside in Venture Global (VG): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Venture Global (VG) points to a 62.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
VGNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
How Much Upside is Left in Fox Factory Holding (FOXF)? Wall Street Analysts Think 35.62%
by Zacks Equity Research
The mean of analysts' price targets for Fox Factory Holding (FOXF) points to a 35.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
FOXFNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Predict a 44.41% Upside in Encore Capital Group (ECPG): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for Encore Capital Group (ECPG) points to a 44.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ECPGNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Predict a 26.55% Upside in Arista Networks (ANET): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 26.6% in Arista Networks (ANET). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
ANETNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think AppLovin (APP) Could Surge 36.45%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for AppLovin (APP) points to a 36.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
APPPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Canaan (CAN) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Canaan (CAN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CANNegative Net Change ALTINegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Flowers Foods (FLO) Reports Next Week: What to Know Ahead of the Release
by Zacks Equity Research
Flowers Foods (FLO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FLONegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Wall Street Analysts Think Lions Gate (LGF.A) Could Surge 27.47%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 27.5% in Lions Gate (LGF.A). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Does Nuvectis Pharma (NVCT) Have the Potential to Rally 108.79% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 108.8% in Nuvectis Pharma (NVCT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
NVCTNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think Roku (ROKU) Could Surge 44.83%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 44.8% in Roku (ROKU). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
ROKUPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 71.07% Upside in Pros Holdings (PRO): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 71.1% in Pros Holdings (PRO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
PROPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think Priority Technology (PRTH) Could Surge 90.76%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 90.8% upside potential for Priority Technology (PRTH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
PRTHNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 219.98% Upside in Syndax (SNDX): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 220% upside potential for Syndax (SNDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
SNDXNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
How Much Upside is Left in Astrazeneca (AZN)? Wall Street Analysts Think 27.89%
by Zacks Equity Research
The consensus price target hints at a 27.9% upside potential for Astrazeneca (AZN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
AZNNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Does Braze (BRZE) Have the Potential to Rally 52.61% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Braze (BRZE) points to a 52.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
BRZEPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
How Much Upside is Left in Altimmune (ALT)? Wall Street Analysts Think 285.86%
by Zacks Equity Research
The mean of analysts' price targets for Altimmune (ALT) points to a 285.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ALTPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Does Amneal (AMRX) Have the Potential to Rally 54.16% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Amneal (AMRX) points to a 54.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
AMRXNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate